TRANSDERMAL FENTANYL: PHARMACOLOGICAL ASPECTS OF THERAPY IN CANCER PATIENTS. PART 1. FROM THE DEVELOPMENT OF TRANSDERMAL FENTANYL FORMULATIONS TILL META-ANALYSES OF CLINICAL TRIALS


Cite item

Full Text

Abstract

There was given a review of data on pharmacology of fentanyl with focus on transdermal formulation. In the first part of the article improvements in technology of fentanyl transdermal patches were reviewed and advantages of the membrane-matrix system that are of practical use were highlighted. The results obtained from bioequivalence and therapeutic equivalence studies of traditional and improved transdermal fentanyl systems were given. Clinical trials with fentanyl transdermal patches as well as systematic reviews and meta-analyses on the efficacy and safety of transdermal fentanyl were summarized. The second part of the article will focus on factors contributing to the variability in pharmacokinetics and pharmacodynamics of fentanyl including pharmacogenetics; the taking into account the whole spectrum of these factors would allow to escaped the majority of errors during the administration of the drug e.g. transdermally. A special attention will be paid to basic principles and issues of the application of fentanyl transdermal therapeutic systems.

About the authors

Aleksander V. Sidorov

Yaroslavl State Medical University

Email: alekssidorov@ya.ru
MD, PhD, DSc, Associate Professor of the Department of Pharmacology, Yaroslavl, 150000, Russian Federation Yaroslavl, 150000, Russian Federation

References

  1. WHO. Cancer Pain Relief. 2nd Ed. 1996/
  2. Каприн А.Д., Абузарова Г.Р., Хороненко В.Э., Алексеева Г.С., Костин А.А., Старинский В.В., Алексеев Б.Я. Фармакотерапия хронического болевого синдрома у взрослых пациентов при оказании паллиативной помощи в стационарных и амбулаторно-поликлинических условиях: Методические рекомендации. М.: ФГБУ «МНИОИ им. П.А. Герцена»; 2015.
  3. Ripamonti C.I., Bandieri E., Roila F. On behalf of the ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann. Oncol. 2012;23 (Suppl. 7): vii139-54.
  4. Доклад Министра здравоохранения Российской Федерации В.И. Скворцовой на заседании итоговой Коллегии Минздрава России «Об итогах работы Министерства здравоохранения Российской Федерации в 2015 году и задачах на 2016 год».
  5. Абузарова Г.Р., Хороненко В.Э., Сарманаева Р.Р. Опиоидные анальгетики для терапии хронической боли у онкологических больных в России. История вопроса и перспективы. Анестезиол. и реаниматол. 2015;60(1):19-25.
  6. Фонарев М.Ю., Черкасов Д.И. Шершакова Л.В. Вопросы обеспечения адекватной опиоидной терапии при оказании паллиативной и других видов медицинской помощи. Вестник Росздравнадзора. 2015; (4): 48-52.
  7. Langford R., McKenna F., Ratcliffe S., Vojtassa´k J., Richarz U. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthr. and Rheum. 2006; 54: 1829-37.
  8. Simpson R.K. Jr., Edmondson E.A., Constant C.F., Collier C. Transdermal fentanyl as treatment for chronic low back pain. J. Pain Symptom Manage. 1997; 14: 218-24.
  9. Ohtori S., Inoue G., Orita S., Eguchi Y., Ochiai N., Kishida S. et al. Transdermal fentanyl for chronic low back pain. Yonsei Med. J. 2012; 53: 788-93.
  10. Pergolizzi J., Boger R., Budd K., Dahan A., Erdine S., Hans G. et al. Opioids and the management of chronic severe pain in the rlderly: Consensus statement of an international expert panel with focus on the six clinically most oftenused World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008; 8(4): 287-313.
  11. Subedi R.K., Oh S.Y., Chun M.K., Choi H.K. Recent advances in transdermal drug delivery. Arch. Pharm Res. 2010; 33(3): 339-51.
  12. Mitragotri S. Breaking the skin barrier. Adv. Drug Deliv. Rev. 2004; 56: 555-6.
  13. Lane M.E. The transdermal delivery of fentanyl. Eur. J. Pharm. Biopharm. 2013; 84(3): 449-55.
  14. Potts R.O., Guy R.H. Predicting skin permeability. Pharm. Res. 1992; 9: 663-9.
  15. Prausnitz M.R., Langer R. Transdermal drug delivery. Nat. Biotechnol. 2008; 26: 1261-8.
  16. Choi H.-K., Flynn G.L., Amidon G.L. Transdermal delivery of bioactive peptides: The effect of n-decylmethyl sulfoxide, pH and inhibitors on encephalin transport. Pharm. Res. 1990; 7: 1099-106.
  17. Moffat A.C., Osselton M.D., Widdop B. (Eds.). Clarke’s Analysis of Drugs and Poisons, 3rd Ed. London: The Pharmaceutical Press; 2004: 1029-30.
  18. Roy S.D., Flynn G.L. Solubility behavior of narcotic analgesics in aqueous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil. Pharm. Res. 1989; 6: 147-51.
  19. Varvel J.R., Shafer S.L., Hwang S.S., Coen P.A., Stanski D.R. Absorbtion characteristics of transdermally administered fentanyl. Anesthesilogy. 1989; 43: 155-62.
  20. Roy S.D., Flynn G.L. Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin. Pharm. Res. 1989; 6: 825-32.
  21. Scott J.C., Cooke J.E., Stanski D.R. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology. 1991; 74(1): 34-42.
  22. Mather L.E. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin. Pharmacokinet. 1983; 8: 422-46.
  23. Leppert W. Pain management in patients with cancer: focus on opioid analgesics. Curr. Pain Headache Rep. 2011; 15: 271-9.
  24. Инструкция по медицинскому применению ТТС бупренорфина (Транстек®).
  25. Инструкция по медицинскому применению ТТС фентанила (Фендивия®).
  26. Roy S.D., Gutierrez M., Flynn G.L., Cleary G.W. Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J. Pharm. Sci. 1996; 85: 491-5.
  27. Kress H.G., Boss H., Delvin T., Lahu G., Lophaven S., Marx M. et al. Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequvivalent. Eur. J. Pharm. Biopharm. 2010; 75: 225-31.
  28. Marier J.F., Lor M., Potvin D., Dimarco M., Morelli G., Saedder E.A. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J. Clin. Pharmacol. 2006; 46: 642-53.
  29. Marier J.F. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation. Br. J. Clin. Pharmacol. 2007; 63: 121-4.
  30. Kress H.G., Von der Laage D., Hoerauf K.H., Nolte T., Heiskanen T., Petersen R. et al. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain. J. Pain Symptom Manage. 2008; 36(3): 268-79.
  31. van Seventer R., Smit J.M., Schipper R.M., Wicks M.A., Zuurmond W.W. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr. Med. Res. Opin. 2003; 19(6): 457-69.
  32. Oztürk T., Karadibak K., Catal D., Çakan A., Tugsavul F., Çırak K. Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer. Agri. 2008; 20(3): 20-5.
  33. Mercadante S., Porzio G., Ferrera P., Fulfaro F., Aielli F., Verna L. et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur. J. Pain. 2008; 12: 1040-6.
  34. Clark A.J., Ahmedzai S.H., Allan L.G., Camacho F., Horbay G.L., Richarz U., Simpson K. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr. Med. Res. Opin. 2004; 20(9): 1419-28.
  35. Yang Q., Xie D.R., Jiang Z.M., Ma W., Zhang Y.D., Bi Z.F., Chen D.L. Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. J. Exp. Clin. Cancer Res. 2010; 29: 67.
  36. Koyyalagunta D., Bruera E., Solanki D.R., Nouri K.H., Burton A.W., Toro M.P. et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician. 2012; 15: ES39-58.
  37. Hadley G., Derry S., Moore R.A., Wiffen P.J. Transdermal fentanyl for cancer pain. Cochrane Database Syst. Rev. 2013; (10): CD010270.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies